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Edited by Horst FeldmannAbstract RNA interference (RNAi) plays a pivotal role in the
regulation of gene expression to control cell development and dif-
ferentiation. In plants, insects and nematodes RNAi also func-
tions as an innate defence response against viruses. Similarly,
there is accumulating evidence that RNAi functions as an antivi-
ral defence mechanism in mammalian cells. Viruses have evolved
highly sophisticated mechanisms for interacting with the host cell
machinery, and recent evidence indicates that this also involves
RNAi pathways. The cellular RNAi machinery can inhibit virus
replication, but viruses may also exploit the RNAi machinery for
their own replication. In addition, viruses can encode proteins or
RNA molecules that suppress existing RNAi pathways or trigger
the silencing of speciﬁc host genes. Besides the natural interplay
between RNAi and viruses, induced RNAi provides an attractive
therapy approach for the ﬁght against human pathogenic viruses.
Here, we summarize the latest news on virus–RNAi interactions
and RNAi based antiviral therapy.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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RNAi is a strongly conserved sequence-speciﬁc gene silencing
mechanism in eukaryotic cells that is induced by double-Abbreviations: AAV, adeno-associated virus; CMV, cytomegalovirus;
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sarcoma-associated virus; MHV6, murine hepatitis virus 6; miRNA,
micro RNA; PFV-1, primate foamy virus type 1; pre-miRNA, precu-
rsor miRNA; RISC, RNA-induced silencing complex; RNAi, RNA
interference; RSV, respiratory syncytial virus; SARS, severe acute re-
spiratory syndrome; shRNA, short hairpin RNA; SIRCT, siRNA
combination therapy; siRNA, small interfering RNA; SV40, simian
virus 40; TAR, trans-activating response region; TRBP, TAR RNA
binding protein; VA-RNAI, virus-associated RNA I; VA-RNAII,
virus-associated RNA II; VSV, vesicular stomatitis virus
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doi:10.1016/j.febslet.2006.02.070stranded RNA (dsRNA). Currently, RNAi has been shown
to function in two distinct processes. The ﬁrst is regulation of
cellular gene expression via microRNAs (miRNAs). miRNAs
represent a family of highly structured small non-coding RNAs
that negatively regulate gene expression at the post-transcrip-
tional level [4]. They are expressed as primary miRNAs (pri-
miRNA) and processed by the proteins Drosha and Dicer into
respectively a 70 nucleotide stem-loop precursor miRNA
(pre-miRNA), and the mature miRNA of 21–25 nts. Only
one strand of the mature miRNA, the guide strand, is loaded
in the RNA induced silencing complex (RISC). The guide
strand targets RISC to the mRNA, where the complex hybri-
dises to (partially) complementary sequences resulting in
mRNA cleavage or translational inhibition (Fig. 1, left panel).
The second function of RNAi is inhibition of incoming
viruses and silencing of transposable elements by generation
of small interfering RNAs (siRNAs 21 nts dsRNA, Fig. 1,
right panel). siRNAs can originate from extensive secondary
RNA structures in the viral RNA or from dsRNA viral repli-
cation intermediates and may be fully complementary to viral
mRNA. After loading into RISC, siRNAs typically trigger
cleavage of the mRNA [2].
Intriguingly, miRNA-mediated gene regulation and antiviral
siRNA activity share Dicer and RISC components, and thus
appear to run along similar pathways. Therefore, viruses are
likely to aﬀect cellular RNAi processes. Recent data indicate
that viruses interact with RNAi mechanisms in various ways,
illustrating genetic variation among diﬀerent virus families.
The antiviral RNAi response might represent a general phe-
nomenon. To counter this response, viruses evolved RNAi
suppressor proteins or RNA molecules with RNAi-modulating
activity. A more distinct virus–RNAi interaction is the recently
reported inhibition of a retrovirus by the cellular miRNA 32
(miR-32). In contrast, hepatitis C virus (HCV) replicates with
the help from the cellular miR-122, another example of speciﬁc
virus–RNAi interaction. We will discuss these complex virus–
host interactions. In addition, we will address the possibility of
RNAi-based antiviral strategies.2. Do animals possess an RNAi-based antiviral mechanism?
RNAi functions as an innate antiviral defence mechanism in
plants, insects and nematodes, but the hypothesis that animals
possess a similar mechanism remains relatively untested. The















































Fig. 1. Viral factors aﬀecting cellular RNAi pathways. miRNA regulated gene expression starts with primiRNAs in the nucleus, which are processed
into mature miRNAs by Drosha and Dicer (left panel). The antiviral RNAi response is triggered by virus-derived dsRNAs during infection (right
panel). Viral RNAi suppressor factors (proteins or decoy RNAs; middle panel) counter these eﬀects. Viruses can also encode miRNA-like molecules
targeting cellular mRNAs. Both RNAi suppressors and viral miRNAs can potentially aﬀect cellular miRNA processing and function (arrows with
question mark).
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antiviral RNAi mechanism.
Perhaps the best evidence for an RNAi-like defence against
virus infection comes from two recent studies with the
nematode Caenorhabditis elegans [46,55]. Wild type and
RNAi-defective cells of this animal were infected with vesicular
stomatitis virus (VSV) engineered to encode a GFP fusion pro-
tein. Upon infection, cells lacking components of the RNAi
apparatus produce more GFP and infectious particles than
the control cells. Furthermore, mutant cells with enhanced
RNAi function were shown to produce less GFP. In this
way, it was demonstrated that multiple genes required for
RNAi are also required for resistance to VSV, suggesting a
natural role for RNAi in the resistance to viruses.
Is there any direct evidence for the production of virus-spe-
ciﬁc siRNA molecules from dsRNA replication intermediates
in infected cells? Recent studies on HIV-1 probably get the
closest to an aﬃrmative answer. Initial attempts to clone vi-
rally encoded siRNAs or miRNAs failed [39], but another
group reported that an miRNA is encoded by the nef region
of the HIV-1 genome [36,37]. In addition, Bennasser and col-
leagues characterized a sequence in the HIV-1 genome that en-
codes a rare siRNA precursor: a hairpin structure composed of
a 19 base pair perfectly complementary stem and a large loop
[5]. This structure is processed by Dicer (or by a Dicer-like
ribonuclease) into functional siRNAs that target the HIV-1
genome. It was reported the Tat protein functions as an RNAi
suppressor protein that blocks the induced antiviral RNAi re-
sponse by interfering with Dicer activity.
RNAi susceptibility of viruses is largely dictated by their
precise replication strategy [23]. For example, RNAi againsthepatitis delta virus (HDV) was only successful for the mRNA
molecule, and not for the genomic and antigenomic RNA se-
quences [15]. The latter two RNA molecules may be resistant
because their location within the nucleus makes them inacces-
sible to the cytoplasmic RISC. Similar ﬁndings have been re-
ported for inﬂuenza virus and respiratory syncytial virus
(RSV). The genomic and antigenomic RNA duplexes of
HDV also resist Dicer cleavage, which appears to be caused
by the extended nature of this imperfect RNA duplex [14]. It
is likely that more diverse viral escape mechanisms will be
identiﬁed in the near future.3. Viral RNAi suppressors
Antiviral RNAi responses are believed to be triggered by vir-
al dsRNA molecules that are produced during infection. To
counter this antiviral eﬀect viruses have evolved strategies to
avoid recognition by the RNAi machinery of the host. Many
plant viruses encode proteins that interfere with one or more
aspects of Dicer action and/or siRNA targeting [31,42,51–
53]. These RNAi suppressors were ﬁrst described as pathoge-
nicity factors, and target the RNAi machinery at various steps
along the silencing pathway, enabling the virus to accumulate
to higher titers. Recently, RNAi suppressors have also been
identiﬁed in several important human pathogenic viruses.
For example, inﬂuenza virus NS1 protein, vaccinia virus E3L
protein, HIV-1 Tat protein and the adenovirus virus-associ-
ated RNAs I and II (VA-RNAI and II) were shown to exhibit
RNAi suppressor activity [2,5,30,32]. This discovery suggests
that RNAi functions as an innate antiviral defence mechanism
2898 B. Berkhout, J. Haasnoot / FEBS Letters 580 (2006) 2896–2902in mammals similar to what has been described in plants and
insects.
The mode of action of RNAi suppressors in human viruses
is largely unknown. We and others have shown that the adeno-
virus VA-RNAs inhibit RNAi by acting as decoy substrates
for Exportin 5 (involved in transport of pre-miRNAs from
the nucleus to the cytoplasm), Dicer and RISC [2,32]. The
HIV-1 Tat protein it thought to block Dicer activity, whereas
inﬂuenza virus NS1 and vaccinia virus E3L may sequester siR-
NAs [5,11,30]. The presence of a viral suppressor function may
have consequences for therapeutic RNAi approaches. For in-
stance, a shRNA therapeutic approach that is dependent on
Dicer processing may not be optimal. However, it is clearly
too early to toss the towel in the ring, as potent HIV-1 inhibi-
tion can be obtained with such an approach [9,18,50,54].4. Virus-encoded miRNAs
Besides suﬀering from the antiviral RNAi responses, viruses
can also exploit RNAi to control the expression of genes of vir-
al or host origin. The ﬁrst example was recently provided for
Epstein Barr virus (EBV), a large DNA virus of the herpes fam-
ily that preferentially infects human B cells [40]. When the small
RNAs from a latently EBV-infected Burkitt’s lymphoma cell
line were cloned, 4% of them originated from two regions of
the EBV genome. A computational method was used to identify
potential targets of these EBV-encoded miRNAs. Among the
predicted targets were regulators of cell proliferation, apopto-
sis, transcriptional regulators and components of signal trans-
duction pathways. Although these targets should be veriﬁed
experimentally, it is striking that several of these genes have
more than one binding site for a particular EBV-miRNA. Deg-
radation of a cellular DNA polymerase was demonstrated
experimentally [40]. Furthermore, the expression of the EBV-
miRNAs was shown to diﬀer in the lytic versus latent stage,
suggesting tight regulation during viral infection. Intriguingly,
the viral miRNAs could be involved in tumour formation
and may explain how EBV hides so well. Other members of
the herpesvirus family and other viruses with a large DNA gen-
ome could encode miRNAs in order to exploit RNAi for the
regulation of host and viral expression.
Extensive cDNA cloning studies across many families of
RNA viruses have failed to identify miRNAs from viruses with
RNA genomes [39]. To date, two other members of the c-her-
pes virus subfamily – Kaposi’s sarcoma-associated virus
(KSHV) and murine gammaherpesvirus 68 (MHV68) – and
one b-herpes virus – cytomegalovirus (CMV) – have been
shown to encode miRNAs [12,34,39,40,45].
KSHV encodes an array of 11 distinct miRNAs from what
appears to be a single genetic locus [12]. All these miRNAs
are expressed at readily detectable levels (up to 2200 copies
per cell) in latently infected cells. Computer analysis of poten-
tial mRNA targets identiﬁed a number of interesting candidate
genes, including several mRNAs previously shown to be down-
regulated in KSHV-infected cells. The miRNAs are fully con-
served in all KSHV isolates present in the genome database,
arguing that they are likely to play a key role in KSHV repli-
cation and pathogenesis. The apparent restriction of viral miR-
NAs to complex DNA viruses may reﬂect an ability of these
viruses to more elegantly manipulate host gene expression rel-
ative to the more stripped-down DNA and RNA viruses.An exception to this may be the small polyomavirus simian
virus 40 (SV40), which encodes a set of miRNAs whose in vivo
target has been clearly deﬁned [48]. The pre-miRNA is part of
a viral late premRNA transcript, but cleaved oﬀ during poly-
adenylation and processed further. The SV40 DNA genome
is circular, such that the late gene sequences are completely
complementary to early mRNAs produced from the opposite
strand. The late miRNA were shown to cleave the early miR-
NAs at the predicted position at late times in the replication
cycle, thus reducing early gene expression, and possibly evad-
ing immune recognition of the infected cell. Again, conserva-
tion of the viral miRNA in other polyomavirus suggests that
it is important for the virus.5. Virus inhibition by a cellular miRNA
Cellular miRNAs are important for the regulation of cellular
genes, but recent evidence indicates that cellular miRNAs can
also target the genetic material of invading viruses. A compar-
ison of the primate foamy virus type 1 (PFV-1) genome and
human miRNAs revealed several miRNAs that could poten-
tially block gene expression and replication of this retrovirus.
When one of these miRNAs, miRNA-32, was knocked down,
the virus nearly doubled its replication rate [28]. Similar to
HIV-1 Tat, the PFV-1 Tas protein was identiﬁed as an RNAi
suppressor protein that was required to block the miRNA
attack on the virus.
The PFV-1 Tas suppressor protein was proposed to have
evolved in response to miRNA-32 inhibition. A seemingly
more simple evolutionary scenario would provide viral escape
by acquisition of one or a few pointmutations within the target
sequence in the viral bet gene. Such changes could even be neu-
tral with respect to the encoded Bet protein when silent codon
changes are selected. Escape from RNAi via this route has
been described for the HIV-1 retrovirus when inhibited by de-
signed shRNA antivirals [8,18,54]. The fact that PFV-1 did not
use this escape route may suggest that, besides the antiviral
RNAi pressure of miR-32, viral sequences themselves also trig-
ger an antiviral RNAi response, similar to antiviral RNAi re-
sponses in plants and insects.6. A cellular miRNA helps HCV
Cellular miRNAs usually act by annealing to the 3 0 non-cod-
ing region of an mRNA, thereby repressing mRNA transla-
tion. Surprisingly, Jopling et al. identiﬁed a liver-speciﬁc
miRNA that interacts with the 5 0 non-coding region of the
HCV RNA genome and seems to aid virus replication [27].
This is the ﬁrst time that an miRNA molecule has been found
to positively regulate gene expression. The human genome
contains at least 800 genes that code for miRNAs. The authors
chose to look at miR-122 because it accounts for 70% of miR-
NAs found in the liver, the place where HCV replicates, there-
by being a major cause of chronic liver disease.
Inhibition of miR-122 function using an antisense oligonu-
cleotide resulted in a dramatic decrease of HCV RNA by
about 80%. With an active miR-122, a mutant HCV RNA with
an altered target sequence in the 5 0 non-coding region failed to
accumulate. Most importantly, this defect could be restored by
ectopic expression of a mutant miR-122 with the compensa-
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RNA. Thus, the replication defect is due to the lack of miR-
122 interaction, and not due to RNA misfolding because of
the 5 0 mutation. The miR-122/HCV RNA interaction does
not primarily inﬂuence RNA translation or stability, but likely
aﬀects viral RNA replication.
The involvement of miR-122 in HCV replication is reminis-
cent to the usage of tRNAlys 3 to prime reverse transcription
during HIV-1 replication [1]. These viruses use available cellu-
lar resources for their own replication. However, miR-122
involvement in HCV replication contrasts with the inhibitory
eﬀect of miR-32 on PFV-1. Apparently viruses can interact
with cellular RNAi factors in various ways. Possibly, other vir-
al of host cell mRNAs can also be positively aﬀected by miR-
NAs. Two plant miRNAs have been demonstrated to interact
with the 5 0 non-coding region of their respective targets
mRNAs [10], but this has not yet been observed for animal
miRNAs [4]. Another intriguing question is about the natural
function of miR-122 in the liver, and whether that function is
inﬂuenced by HCV infection. These results also have potential
therapeutic relevance. First, knocking down miR-122 in the li-
ver might counteract infection with HCV. Second, antiviral si/
shRNA strategies could focus on the miR-122 target in the 5 0
non-coding region. This target may be highly accessible and is
likely to be extremely conserved to maintain miR-122 interac-
tion. As such, viral escape would be extremely diﬃcult, thus
allowing the development of a durable therapy.7. Viruses that aﬀect the cellular RNAi machinery
Viruses are capable of exploiting cellular resources for their
own replication, and they frequently modulate cellular path-
ways to optimize replication. It is becoming increasingly clear
that there is also an intricate relationship between viruses and
the cellular RNAi machinery. As we mentioned earlier, miRNA
regulated cellular gene expression and the antiviral siRNA
activity appear to run along similar pathways (Fig. 1). We dis-
cussed examples in which cellular miRNAs inhibit and promote
virus replication. Viral RNAi suppressor factors that block Di-
cer or siRNA function may aﬀect cellular miRNA function in
case they cannot discriminate between siRNA and miRNA
processing. In that scenario, suppressors will not only inhibit
the antiviral RNAi eﬀect, but also interfere with cellular miR-
NAs function. Such suppressor induced changes in miRNA
maturation will indirectly aﬀect cellular gene expression, and
may contribute to viral pathogenicity. In plants, the turnip mo-
saic virus RNAi suppressor protein HC-Pro blocks miR171
activity, resulting in abnormal plant development [26]. In hu-
man cells, adenovirus VA-RNAI was shown to interfere with
miRNA biogenesis [2,32]. For HIV-1, the Tat protein was
shown to partially repress the processing activity of Dicer [5].
Indeed, the miRNA expression proﬁle was recently demon-
strated to diﬀer in cells that express HIV-1 when compared to
control cells [16]. This initial study was performed with cells
transfected with an HIV-1 molecular clone, and should be re-
peated with virus infected primary human cells. It is conceiv-
able that the downregulation of mature miRNAs may be due
to the Dicer suppressive eﬀect exerted by the Tat protein [5].
Another intriguing link betweenHIV-1 and the cellular RNAi
machinery became apparentwith the identiﬁcation ofTRBPas a
protein partner of humanDicer. TRBPwas previously identiﬁedas HIV-1 TAR RNA-binding protein [19]. Two recent studies
indicate that TRBP is a component that is required for RISC
assembly and optimal RNA silencing mediated by siRNAs
and endogenous miRNAs [16,21]. TRBP had previously been
assigned several functions, including inhibition of the inter-
feron-induced (IFN)dsRNA-regulated protein kinase PKR
and modulation of HIV-1 gene expression by association with
TAR. The TRBP–Dicer interaction raises the possibility of
crosstalk between RNAi and IFN-PKR pathways, both in nor-
mal and virus-infected cells. Interestingly, many RNAi suppres-
sors encoded by viruses are also inhibitors of the IFN-induced
PKR, providing another overlap between these two pathways.
The ﬁnding that TRBP is an essential component of the RISC
complex raises several possible scenarios for HIV-1 interference
with the RNAi pathway [20]. For instance, accumulation of
HIV-1 RNA with 5 0 and 3 0 TAR motifs in virus-infected cells
may trigger the depletion of TRBP, leading to inactivation of
RISC and the RNAi machinery. This could facilitate a general
suppression of RNAi byHIV-1, similar to the way in which ade-
novirus VARNAs block Exportin-5, Dicer and RISC.
Several alternative scenarios can be proposed. TAR has sec-
ondary structure that resembles miRNA precursors, raising
the possibility that TAR is a viral pre-miRNA. Combined with
the recent ﬁnding that the Tat protein is a suppressor of RNAi,
and in particular an inhibitor of Dicer [5], these observations
may suggest that TRBP could recruit Dicer to TAR only in
the absence of Tat, resulting in functional destruction of
HIV-1 transcripts [43]. Tat may prevent this antiviral action.
Any of these speculative models should incorporate the fact
that TRBP contributes to HIV-1 replication [20]. All scenarios
obviously require experimental testing. For instance, despite
the use of sensitive reporter assays, we never obtained any evi-
dence for functional dicing of TAR in cells (Haasnoot and
Berkhout, unpublished results).8. RNAi based antiviral therapy
The ﬁrst demonstration of RNAi-mediated inhibition of a
human pathogenic virus was reported by Bitko and Barik in
2001 [7]. These authors reported a 10-fold inhibition of RSV
replication in vitro using nanomolar concentrations of syn-
thetic siRNAs that targeted RNAs encoding the viral polymer-
ase subunit P and the fusion protein F. Currently, many other
studies have described RNAi-mediated inhibition of a large
variety of viruses. RNAi-mediated inhibition of HIV-1 has re-
ceived much attention. In addition, 25 diﬀerent RNA viruses,
and 11 diﬀerent DNA viruses have been eﬃciently targeted
by RNAi [22]. These include important human pathogens such
as HCV, dengue (DEN) virus, severe acute respiratory syn-
drome (SARS) coronavirus, poliovirus, inﬂuenza A virus,
HDV, human rhinovirus (HRV), hepatitis B virus (HBV), her-
pes simplex virus type-1 (HSV-1), human papillomavirus
(HPV), JC virus (JCV), EBV, and CMV.
Initially, the standardmethod to induce RNAi against viruses
inmammalian cellswas transfection of synthetic siRNAs shortly
before or after viral challenge. Currently, transient transfection
of plasmids that express antiviral shRNAs is also commonly
used. Both strategies can result in potent, albeit temporary inhi-
bition of virus replication. In order to obtain long-term virus
resistance, researchers have turned to a combined RNAi/gene
therapy approach. In this approach, lenti-, retro- or adeno-asso-
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constructs expressing shRNA, resulting in viral resistance.9. HIV-1 inhibition by RNAi, viral escape and human
countermeasures
Several studies reported that siRNA can suppress HIV-1
[13,17,24,25,29,33,35,38,41,49]. There is some evidence suggest-
ing that the genomic RNA present within an infecting virion
particle is targeted for destruction, but it appears that new viral
transcripts, synthesized from the integrated provirus, are more
eﬃcient targets. Most studies used chemically synthesized siR-
NAs that were transfected into cells either shortly before or
after challenge with HIV-1. Despite the transient nature of such
a transfection experiment, a single siRNA application is able to
achieve relatively long-lasting suppression [47]. Other studies
used transient transfection of siRNA-expression vectors. How-
ever, the development of eﬃcient vector delivery systems capa-
ble of mediating stable siRNA expression in mature T
lymphocytes or progenitor stem cells will be a minimal require-
ment for RNAi to be used as a therapeutic modality against
HIV-1. Lentiviral vectors with a Pol III expression cassette
are an eﬃcient means to deliver anti-HIV siRNAs into haema-
topoietic precursor cells. In a recent report, the transduced hu-
man cells were allowed to diﬀerentiate in vivo in the SCID-hu
thymopoiesis mouse model [3], and the mature T lymphocytes
derived from this model resisted HIV-1 infection ex vivo.
Two studies addressed the potency and durability of anti-HIV
RNAi approaches. Boden et al. expressed an shRNAagainst the
tat gene in anAAV vector with anH1-promoter [8]. Potent inhi-
bition was scored, but an escape virus variant appeared in pro-
longed cultures. Similar results were described by Das et al.
using a lentiviral vector with an H1 unit expressing an siRNA
against sequences in the nef gene [18]. The latter study described
seven independent HIV-1 escape variants. The combined results
convincingly demonstrate that inhibition was potent and se-
quence-speciﬁc, but also that HIV-1 is able to escape from the
inhibitory action of a single siRNA. Boden et al. described a sin-
gle revertant with a point mutation in the target sequence, and
Das et al. described a large variety of escape routes (point muta-
tion, double point mutation, partial or complete deletion of the
target sequence). A deletion-based resistance mechanism seems
impossible in case essential HIV-1 genes or critical sequencemo-
tifs are targeted. Thus, one should preferentially target essential
sequences that are well conserved among HIV-1 isolates. Inter-
esting targets with relatively little mutational freedom are the
multiple overlaps in reading frames within the HIV-1 genome,
including a triple overlap (tat–rev–env). Ideally, one should tar-
get more than one of these essential and well-conserved viral se-
quences. Such siRNAcombination therapy (SIRCT)mimics the
successful strategy to combat HIV-1 with multiple antiviral
drugs, and should avoid the evolution of escape variants [6].
We recently discovered an alternative resistance mechanism
that is not triggered by mutation of the target sequence. In-
stead, a mutation in the ﬂanking sequences was selected, which
was subsequently shown to induce a conformational change
within the target sequence such that it is protected from RISC
attack [54]. This ﬁnding indicates that it will not be very
straightforward to predict viral escape routes. Nevertheless,
one could make a ﬁrst estimation of the chance of viral escape
in a therapeutic setting with one or multiple siRNAs [6]. If weassume that an essential viral sequence is targeted, deletion is
no option. Therefore, one and more likely two nucleotide sub-
stitutions are required per 19-nucleotide target sequence to ob-
tain a fair level of resistance [18]. Assuming that 2-point
mutations are needed to obtain complete resistance, and fur-
ther assuming an error rate of the reverse transcriptase poly-
merase of 2 · 105, the chance of viral escape in a single
replication cycle is 19 · [(2 · 105)]2 = 1.44 · 107. Studies in
the ﬁeld of drug-resistance indicate that an untreated HIV-in-
fected individual contains an eﬀective viral population size of
104–105 [44], which means that most 1-nucleotide substitutions
will already be present within the viral population. Starting in
an untreated patient with a moderate viral load, this means
that resistance is likely to occur. Thus, it may indeed be impor-
tant to consider SIRCT [6]. With four eﬀective siRNAs, the
chance of viral escape drops to 2.1 · 1014. In practice, this
means that viral escape is impossible as long as viral suppres-
sion is complete. Even if several assumptions are wrong, the
prospects are favourable that one can achieve eﬀective and
long-term viral suppression. An alternative strategy is to target
unmutable host-encoded functions that are important for viral
replication, but not essential for survival of the host cell.10. Concluding remarks
Viruses are obligate intracellular parasites whose replication
depends on their hosts. This interplay has important conse-
quences, both for the virus and the host. RNAi is a newly dis-
covered mechanism that, through miRNA eﬀector molecules,
plays a pivotal role in the regulation of many genes, especially
those at nodes of signaling pathways involved in such processes
as development, metabolism, apoptosis and aging. It therefore
comes as no surprise that viruses also encode miRNAs. In addi-
tion, host-encoded miRNAs have been reported to positively or
negatively modulate viral replication. On their part, viruses can
encode RNAi suppressors that protect against the cellular anti-
viral RNAi response, but that may also aﬀect cellular gene
expression. Certain viruses even have evolved to utilize that
miRNA pathway to their own advantage. Nevertheless, a bet-
ter understanding of the virus–host interaction at the molecular
level should allow us to develop an eﬀective, durable and non-
toxic antiviral therapy. RNAi-based treatments are quickly
moving towards human patients, and the year 2006 should oﬀer
the ﬁrst hints of how this highly publicized technique works in a
therapeutic setting. Company-funded clinical trials in macular
degeneration are under way, and targeting of transient viral
infections such as pediatric respiratory illness caused by RSV
are supposed to launch soon. Chronic viral infections caused
by HCV and HIV-1 will follow.
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